Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Herpes Zoster subunit (HZ/su) vaccine in adults 18 years of age or older with renal transplant

Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.

• A male or female, aged 18 years or older and having reached the age of legal consent, on the date the informed consent is signed.
• Written informed consent obtained from the subject.
• Subject who has received an ABO compatible allogeneic renal transplant.
• Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to the first vaccination.
• Subject without an episode of allograft rejection over the previous three months (90 days) prior to the first vaccination.
• Subject with stable renal function, stability defined as:

or in the opinion of the investigator after investigator review of more than the last two creatinine measurements or calculated GFRs.

• Subject not less than 4 months (120 days) and not more than 18 months (547 days) after allograft transplantation at the time of the first vaccination.
• Subjects with multiple dialysis options (peritoneal and/or more than one anatomical access site for haemodialysis) in the event acute or chronic dialysis is needed.
• Female subjects of non-childbearing potential may be enrolled in the study.
• Female subjects of childbearing potential may be enrolled in the study, if the subject:

Any primary kidney disease with a high incidence of recurrent primary kidney disease.

• Evidence of recurrent primary kidney disease within the current allograft.
• Previous allograft loss secondary to recurrent primary kidney disease.

Multiple kidney transplants are allowed if the reason for a previous allograft’s loss is not recurrent primary kidney disease.

• More than one organ transplanted (i.e. kidney-liver, double kidney or kidney-other organ(s) transplanted).
• History of events that, in the opinion of the investigator, may put subject at increased risk for chronic allograft dysfunction (e.g. delayed graft function, peri-operative complications).
• Histologic reports of chronic allograft injury (e.g. transplant glomerulopathy, arteriopathy, C4d deposition).
• Evidence of significant proteinuria in the opinion of the investigator.
• Panel reactive antibody score (PRA or cPRA) that is unknown at the time of transplant.
• Any autoimmune or potential immune-mediated disease including primary kidney disease.
• Use of anti-CD20 or other B-cell monoclonal antibody agents (e.g., rituximab) as induction, maintenance and/or therapeutic immunosuppressive therapy for the prevention of allograft rejection within 9 months (274 days) of first dose of study vaccine/placebo.
• Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.
• Concurrent or planned participation in another clinical study, at any time during the study period, which has exposed or will expose the subject to an investigational or a non-registered product
• Administration or planned administration of a live vaccine within 30 days prior to the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
• Planned administration during the study of a varicella or HZ vaccine other than the study vaccine.
• Previous vaccination against HZ or varicella within the 12 months preceding the first dose of study vaccine/placebo.
• Occurrence of varicella or HZ per clinical history, within the 12 months preceding the first dose of study vaccine/placebo.
• Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit.
• Evidence or high suspicion, in the opinion of the investigator, of noncompliance or nonadherence to use of induction and/or maintenance immunosuppressive therapies.
• Any confirmed or suspected HIV, primary immunodeficiency disease, disseminated or untreated malignancy, or systemic infection.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine or study material and equipment.
• Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.
• Any other condition that, in the opinion of the investigator, might interfere with the evaluations required by the study.
• Acute disease and/or fever at the time of vaccination.

Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.

• Pregnant or lactating female.
• Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) before Month 3.